Administration of DAB389IL-2 to patients with recalcitrant psoriasis: A double-blind, phase II multicenter trial

Journal of the American Academy of Dermatology

Volumn 38, Issue 6 I, 1998, Pages 938-944

  Bagel, J ^a   Garland, W T ^a   Breneman, D ^a   Holick, M ^a   Littlejohn, T W ^a   Crosby, D ^a   Faust, H ^a   Fivenson, D ^a   Nichols, J ^a  

^a Central New Jersey   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAB 389; HYBRID PROTEIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; UNCLASSIFIED DRUG; DENILEUKIN DIFTITOX; DIPHTHERIA TOXIN;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFLUENZA; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; VASOSPASM; FEMALE; MALE; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; DIPHTHERIA TOXIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERLEUKIN-2; MALE; MIDDLE AGED; PSORIASIS; RECOMBINANT FUSION PROTEINS;

EID: 0032085463     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(98)70590-0     Document Type: Article

References (12)

1. BS Baker CEM Griffiths S Lambert AV Powles JN Leonard H Valdimarsson Effect of cyclosporin A on T-lymphocyte and dendritic cell sub-populations in psoriasis Br J Dermatol 116 1987 503 510
2. 389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis Nat Med 1 1995 442 447
3. V Strand PE Lipsky GW Cannon LH Calabrese C Wiesenhutter SB Cohen Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis: results of two phase II studies Arthritis Rheum 36 1995 620 630
4. DP Williams CE Snider TB Strom JR. Murphy Structure/function analysis of interleukin-2-toxin (DAB 486-IL-2) J Biol Chem 265 1990 11885 11889
5. T Takeshita H Asao K Ohtani N Ishii S Kumaki N Tanaka Cloning of the g chain of the IL-2 receptor Science 257 1992 379 382
6. JW Lowenthal HR MacDonald BJ. Iacopetta Intracellular pathway of interleukin 2 following receptor-mediated endocytosis Eur J Immunol 16 1986 1461 1463
7. BA Wilson RJ. Collier Diphtheria toxin and Pseudomonas aeruginosa exotoxin A: active-site structure and enzymic mechanism Microbiol and Immunol 175 1992 27 41
8. 389IL-2, for the treatment of psoriasis Dermatol Ther 5 1998 48 63
9. T Fredriksson U. Pettersson Severe psoriasis: oral therapy with a new retinoid Dermatologica 157 1978 238 244
10. AY Finlay GK. Khan Dermatology life quality index (DLQI): a simple practical measure for routine clinical use Clin Exp Dermatol 19 1994 210 216
11. The European FK 506 Multicentre Psoriasis Study Group Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study Arch Dermatol 132 1996 419 423
12. J Prinz O Braun-Falco M Meurer P Daddona C Reiter P Reiber G. Riethmüller CD4 antibody treatment of severe psoriasis Lancet 338 1991 322 332